AGA Technical Review on Systemic Therapies for Hepatocellular Carcinoma

AGA Clinical Practice Guideline on Systemic Therapy for Hepatocellular Carcinoma

“…A detailed synthesis of the evidence from which these recommendations were formulated can be found in the accompanying Technical Review (TR). 5…”

“…Development of this guideline (and the accompanying Technical Review) 5 was fully funded by the AGA Institute without any additional outside funding.…”

Loss of the Novel Mitochondrial Membrane Protein FAM210B Is Associated with Hepatocellular Carcinoma

“…Hepatocellular carcinoma (HCC) is responsible for 85% of all liver cancer cases and is a particularly aggressive subtype of the disease [ 1 , 2 ]. Although surgical interventions and other medical therapies have improved survival rates for patients with early-stage HCC, the disease remains a significant threat to human health due to its high surgical risk and recurrence rate [ 3 , 4 , 5 ]. Cell hyperproliferation is the initial step in the development of HCC, which progresses into carcinoma in situ, to invasive carcinoma, and eventually to metastatic illness.…”

Is multidisciplinary treatment effective for hepatocellular carcinoma with portal vein tumor thrombus?

“…2,3 Treatment with regorafenib as second-line treatment has been demonstrated to extend survival by approximately 3 months. 4 However, even with the same BCLC C stage, the extent of the PVTT may also affect the patient prognosis. 5 Recently, HCC treatment approaches, such as hepatic resection, transarterial chemoembolization, radiation therapy, transarterial radioembolization (TARE) with yttrium-90, hepatic arterial infusion chemotherapy (HAIC), molecular targeted therapy, and immune therapy, have greatly advanced.Based on various retrospective clinical studies, it has been demonstrated that combination treatment or multidisciplinary management using the aforementioned treatments can improve the survival of patients with advanced HCC.…”

“… 2 , 3 Treatment with regorafenib as second-line treatment has been demonstrated to extend survival by approximately 3 months. 4 However, even with the same BCLC C stage, the extent of the PVTT may also affect the patient prognosis. 5 …”